A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma
The goal of this clinical research study is to learn if pembrolizumab (MK-3475) can help to control the disease better than brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. The safety of these drugs will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 08/01/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: